Wilson's disease (WD) is a progressive autosomal recessive disorder characterised by impaired copper transport and excessive accumulation of copper in the liver, brain, and other tissues. It has been named after S. A. Kinnier Wilson, who fi rst described it in detail in Brain in 1912, addressing both pathological and clinical manifestations (1).
Wilson's disease is caused by a mutation in the ATP7B gene, located in chromosome 13, which encodes a Copper-Binding P-type ATPase, expressed dominantly in the liver cells and vital for the transmembrane transport of copper (2) (3) (4) (5) . Impaired function of this enzyme leads to decreased excretion of copper from the liver cells into bile. Consequently, copper accumulates in the liver cells, disrupting their structure and function. In addition, it is released into the blood stream and transported to other target organs such as the brain, kidneys, and eyes, where it also accumulates and does damage.
It is a rare disease, with average prevalence of 30 per million population (6, 7) . Its diagnosis is based on clinical manifestations and screening test results. Clinical manifestations include liver disease (hepatitis, cirrhosis, liver failure), progressive neurological disorder (dystonia, tremor, dysphagia, dysarthria), and a psychiatric illness (depression, cognitive and emotional impairment) (7, 8) . Screening tests include 24-h urine copper excretion, serum and urine copper levels, ceruloplasmin serum level, and eye examination for Kayser-Fleischer ring with a slit lamp. The definitive diagnostic test is quantitative analysis of copper in a dry liver tissue sample obtained by percutaneous liver biopsy (9) .
Work ability assessment of patients with WD is based on the analysis of liver, kidney, neurological, and cognitive impairment, and takes into account patient's level of education (10) .
CASE REPORT
A 48-year old male patient D. M. was admitted for work ability assessment to the Serbian Institute for Occupational Health. His main symptoms were weakness in arms and legs, tremor, general fatigue, insomnia, headache, anxiety, blurry vision, forgetfulness, and vertigo.
Patient's history revealed that he had a severe hepatitis-like liver disease at the age of 10, that he was diagnosed Wilson's disease at the age of 13, and that he had been treated with D-penicillamine from the age of 14. The fi rst administration of D-penicillamine worsened the symptoms and led to high fever and intense neurological problems, including a weakness of the left arm and leg, dysphagia, and dysarthria. Withdrawal of D-penicillamine relieved the symptoms, but some neurological issues remained. Since then, the patient had been monitored closely, as he continued treatment with D-penicillamine (500 mg three times a day) and pyridoxine oral preparations (20 mg three times a day). Over the last three years, his health got worse, especially the neurological problems, and he developed new psychiatric and vision problems (blurry vision, impaired vision of the left eye). He denied having any new manifestations of the liver disease, but he had been told at earlier examinations that he had enlarged liver and spleen. The patient reported no other co-morbidities of interest or allergies; he did not smoke and did not drink alcohol.
Family history revealed that his mother had died of liver tumour, but none of his close relatives suffered from other chronic illnesses.
Occupational history showed that the patient had fi nished primary school, but could not pursue further education, except basic vocational training for a salesperson, due to a "learning disability" to use his own words. He had been selling alcoholic and nonalcoholic drinks for 28 years. The initial clinical examination performed by an occupational health specialist revealed that the patient was obese, had normal vital signs, distended abdomen painful on palpation, and signs of enlarged liver at the level of the right rib arch. Upper extremities showed signs of involuntary tremor, and lower legs were swollen and skin hyperpigmented bilaterally.
To confi rm previous WD diagnosis, we performed screening tests. Abdominal ultrasound confi rmed enlarged liver (cephalic-caudal diameter of the right lobe was 16 cm) in the state of compensated cirrhosis and enlarged spleen (15.5 cm x 6 cm) with signs of portal hypertension.
Detailed neurological examination showed spasmodic dystonia and muscle weakness of the left arm, weakness and slower refl exes of the left leg, positive Romberg test, and severe dysarthria. On MRI, T2-weighted images revealed hyperintensities in the region of tegmentum mesencephali and putamen bilaterally. Cortical and subcortical reduction changes were also seen, as well as microvascular ischemic lesions in the region of centrum semiovale.
A detailed psychological and psychiatric examination showed borderline intelligence (IQ=78), with indicators of secondary cognitive deficit. Cognitive functions were substantially diminished. There were signs of emotional lability with autoagressive behaviour. There were no data available that would indicate any cognitive or emotional issues during early childhood, that is, before the first manifestations of the illness came through or before the initial D-penicillamine treatment.
Eye examination with a slit lamp showed no presence of Kayser-Fleischer rings, but there were signs of hypermetropia, presbyopia, and anysometropia. The difference between the left and the right eye was more than 3 dioptres.
Dermatological examination showed signs of stasis dermatitis due to compromised peripheral circulation in the lower extremities.
DISCUSSION
Initial clinical manifestations of Wilson's disease can involve neurological (in 40 % to 60 % of the patients) or liver function impairments (in 40 % to 50 % of the patients) (7). Earlier onset of the disease is more often seen in patients with liver disease (11.4 years vs. 18.9 years in patients with neurological forms) (11) . When diagnosed WD at the age of 13, our patient had acute hepatitis-like symptoms and signs. They seem to appear fi rst in over 25 % of WD patients (12) . Current liver function in our patient is also very common and involves progressive hepatic cirrhosis with enlarged liver and spleen and signs of portal hypertension. This level of liver disease alone is a contraindication for any kind of work that involves lifting heavy loads and dealing with hepatotoxic chemical agents (10) .
Neurological impairment in WD can be classified as: (a) an akinetic-rigid syndrome similar to Parkinson's disease, (b) pseudosclerosis dominated by tremor, (c) ataxia, and (d) a dystonic syndrome (13) . Our patient mostly had dystonic manifestations, with some elements of pseudosclerosis.
Characteristic MRI changes in WD patients include lesions in the putamen, globus pallidus, caudate, thalamus, midbrain, pons, and cerebellum as well as cortical atrophy and white matter changes. In general, these lesions show high T2 and low T1 signal intensity (15) . Our patient's MRI showed hyperintensities in the region of tegmentum mesencephali and putamen bilaterally. In addition, we observed cortical and subcortical reduction changes, which are in line with MRI changes characteristic for WD.
Neurological manifestations of Wilson's disease usually include resting or postural tremor, dysarthria (85 to 97 % of those with neurologic WD have this sign) (15) , dystonia (11% to 65 % of WD patients) (16), dysphagia, drooling, headaches, and insomnia (9). Our patient had dominantly suffered from spasmodic dystonia of the left arm and leg and from severe dysarthria, vertigo, headaches, and insomnia.
In terms of work ability, this level of neurological impairment in conjunction with specifi c MRI changes is contraindicated for any kind of work, due to tremor, muscle weakness, and speech problems, but most of all, due to progressive and irreversible nature of the disease itself (17) .
Psychiatric manifestations like depression, personality changes, and cognitive impairment are present in 20% to 65 % of patients with WD, especially in those with dominant neurological form the disease (12) . Psychiatric examination of our patient showed signs of emotional lability with autoagressive behaviour, borderline intelligence, and diminished cognitive functions. These characteristics alone indicate work disability for all jobs that include psychological or physical strain.
Kayser-Fleischer (KF) rings are very common in patients with neurological and psychiatric manifestations of Wilson's disease, but our patient had never had them. Ross et al. (18) have also reported about the absence of Kayser-Fleischer rings in patients with WD (18) .
One of the basic aims of medical treatment of WD is to eliminate excess copper from the body and to prevent its further accumulation. In 1956, John Walshe (19) introduced D-penicillamine as a successful copper chelating agent. D-penicillamine stimulates urinary excretion of copper and promotes the synthesis of metallothionein, which in turn prevents tissue accumulation of copper. D-penicillamine is still one of the most important medications in the treatment of WD, but its wide use has shown some downsides. Initial high doses of D-penicillamine can further impair the neurological function of WD patients, and this impairment has been reported to persist in as many as 50 % of patients after stopping D-penicillamine treatment (7, 20) . These fi ndings are in compliance with our patient's history, as he showed worsening of neurological symptoms after the drug was introduced at the age of 14 and their persistence after it was stopped.
What is peculiar in this case is that no other medication (except pyridoxine supplementation) was included in our patient's treatment. Nowadays zinc acetate, trientine, and ammonium tetrachydromolibdate are drugs of choice if D-penicillamine shows adverse effects (9) . Furthermore, receiving 1500 mg of Dpenicillamine every day for 35 years could be one of the reasons for his progressive neurological deterioration over the past three years.
CONCLUSIONS
Work ability assessment in patients suffering from Wilson's disease most of all depends on the level of organ impairment (10, 17) . Our patient had initially presented with the hepatic form of WD, complicated with neurological and cognitive impairment due to adverse effects of high dose D-penicillamine treatment. These cognitive impairments may have led to learning disabilities that limited our patient's educational and occupational potentials. Due to early diagnosis and close monitoring, his liver function had been preserved for long; after 35 years with the diagnosis and 28 years of hard work, liver impairment was only at the level of compensated liver cirrhosis and portal hypertension. His neurological and psychiatric manifestations, on the other hand, had progressed far more after longterm use of high-dose D-penicillamine, and are now the main reason for his drastically diminished work ability.
Even though our patient did not have eye manifestations of WD like KF rings and sunfl ower cataract, non-specifi c vision problems (hypermetropia, presbyopia, and anysometropia), mild trombocytopenia, and compromised peripheral circulation in the lower extremities also contributed to his work disability.
